Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,874
  • Shares Outstanding, K 2,012
  • Annual Sales, $ 27,470 K
  • Annual Income, $ -20,370 K
  • 60-Month Beta 1.65
  • Price/Sales 0.23
  • Price/Cash Flow N/A
  • Price/Book 1.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +768,561.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.64 +4.17%
on 11/12/19
4.98 -44.78%
on 10/17/19
-1.42 (-34.10%)
since 10/14/19
3-Month
2.55 +7.84%
on 08/28/19
5.80 -52.63%
on 10/11/19
-0.85 (-23.55%)
since 08/14/19
52-Week
2.55 +7.84%
on 08/28/19
20.70 -86.71%
on 12/14/18
-13.33 (-82.90%)
since 11/14/18

Most Recent Stories

More News
Cancer Genetics, Inc. Announces Strategic Transactions

Note Payment Received from Interpace Diagnostics Group, Inc.

CGIX : 2.70 (-7.53%)
IDXG : 0.69 (-12.66%)
Cancer Genetics Announces 1-for-30 Reverse Stock Split

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding...

CGIX : 2.70 (-7.53%)
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...

CGIX : 2.70 (-7.53%)
IDXG : 0.69 (-12.66%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ --

CGIX : 2.70 (-7.53%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

https://mma.prnewswire.com/media/1008171/Datar_Cancer_Genetics_Limited_Logo.jpg

CGIX : 2.70 (-7.53%)
Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the second quarter...

CGIX : 2.70 (-7.53%)
Cancer Genetics, Inc. Announces Strategic Transactions

Sale of BioPharma business to Interpace Diagnostics Group, Inc.

CGIX : 2.70 (-7.53%)
IDXG : 0.69 (-12.66%)
Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business Supported by Investment from Ampersand Capital Partners

Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET

IDXG : 0.69 (-12.66%)
CGIX : 2.70 (-7.53%)
NHLD : 2.80 (+2.19%)
Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer

Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment...

CGIX : 2.70 (-7.53%)
INNT : 0.81 (+1.23%)
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

DGX : 102.80 (+0.46%)
LH : 169.45 (+1.36%)
CGIX : 2.70 (-7.53%)
ICLR : 152.52 (+1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CGIX with:

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

2nd Resistance Point 3.18
1st Resistance Point 3.05
Last Price 2.70
1st Support Level 2.81
2nd Support Level 2.70

See More

52-Week High 20.70
Fibonacci 61.8% 13.77
Fibonacci 50% 11.63
Fibonacci 38.2% 9.48
Last Price 2.70
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar